Search

Your search keyword '"Pass, Martin"' showing total 187 results
Start Over Author "Pass, Martin"
187 results on '"Pass, Martin"'

1. Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood–Brain Barrier: The Discovery of AZD1390

Author

Pike, Kurt G., primary, Hunt, Thomas A., additional, Barlaam, Bernard, additional, Benstead, David, additional, Cadogan, Elaine, additional, Chen, Kan, additional, Cook, Calum R., additional, Colclough, Nicola, additional, Deng, Chao, additional, Durant, Stephen T., additional, Eatherton, Andrew, additional, Goldberg, Kristin, additional, Johnström, Peter, additional, Liu, Libin, additional, Liu, Zhaoqun, additional, Nissink, J. Willem M., additional, Pang, Chengling, additional, Pass, Martin, additional, Robb, Graeme R., additional, Roberts, Caroline, additional, Schou, Magnus, additional, Steward, Oliver, additional, Sykes, Andy, additional, Yan, Yumei, additional, Zhai, Baochang, additional, and Zheng, Li, additional

Published
2024
Full Text
View/download PDF

2. Video 1 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Author

Karlin, Jeremy, primary, Allen, Jasmine, primary, Ahmad, Syed F., primary, Hughes, Gareth, primary, Sheridan, Victoria, primary, Odedra, Rajesh, primary, Farrington, Paul, primary, Cadogan, Elaine B., primary, Riches, Lucy C., primary, Garcia-Trinidad, Antonio, primary, Thomason, Andrew G., primary, Patel, Bhavika, primary, Vincent, Jennifer, primary, Lau, Alan, primary, Pike, Kurt G., primary, Hunt, Thomas A., primary, Sule, Amrita, primary, Valerie, Nicholas C.K., primary, Biddlestone-Thorpe, Laura, primary, Kahn, Jenna, primary, Beckta, Jason M., primary, Mukhopadhyay, Nitai, primary, Barlaam, Bernard, primary, Degorce, Sebastien L., primary, Kettle, Jason, primary, Colclough, Nicola, primary, Wilson, Joanne, primary, Smith, Aaron, primary, Barrett, Ian P., primary, Zheng, Li, primary, Zhang, Tianwei, primary, Wang, Yingchun, primary, Chen, Kan, primary, Pass, Martin, primary, Durant, Stephen T., primary, and Valerie, Kristoffer, primary

Published
2023
Full Text
View/download PDF

3. Video 4 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Author

Karlin, Jeremy, primary, Allen, Jasmine, primary, Ahmad, Syed F., primary, Hughes, Gareth, primary, Sheridan, Victoria, primary, Odedra, Rajesh, primary, Farrington, Paul, primary, Cadogan, Elaine B., primary, Riches, Lucy C., primary, Garcia-Trinidad, Antonio, primary, Thomason, Andrew G., primary, Patel, Bhavika, primary, Vincent, Jennifer, primary, Lau, Alan, primary, Pike, Kurt G., primary, Hunt, Thomas A., primary, Sule, Amrita, primary, Valerie, Nicholas C.K., primary, Biddlestone-Thorpe, Laura, primary, Kahn, Jenna, primary, Beckta, Jason M., primary, Mukhopadhyay, Nitai, primary, Barlaam, Bernard, primary, Degorce, Sebastien L., primary, Kettle, Jason, primary, Colclough, Nicola, primary, Wilson, Joanne, primary, Smith, Aaron, primary, Barrett, Ian P., primary, Zheng, Li, primary, Zhang, Tianwei, primary, Wang, Yingchun, primary, Chen, Kan, primary, Pass, Martin, primary, Durant, Stephen T., primary, and Valerie, Kristoffer, primary

Published
2023
Full Text
View/download PDF

4. Data from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Author

Guichard, Sylvie M., primary, Curwen, Jon, primary, Bihani, Teeru, primary, D'Cruz, Celina M., primary, Yates, James W.T., primary, Grondine, Michael, primary, Howard, Zoe, primary, Davies, Barry R., primary, Bigley, Graham, primary, Klinowska, Teresa, primary, Pike, Kurt G., primary, Pass, Martin, primary, Chresta, Christine M., primary, Polanska, Urszula M., primary, McEwen, Robert, primary, Delpuech, Oona, primary, Green, Stephen, primary, and Cosulich, Sabina C., primary

Published
2023
Full Text
View/download PDF

5. Supplemenary Figure 2 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Author

Guichard, Sylvie M., primary, Curwen, Jon, primary, Bihani, Teeru, primary, D'Cruz, Celina M., primary, Yates, James W.T., primary, Grondine, Michael, primary, Howard, Zoe, primary, Davies, Barry R., primary, Bigley, Graham, primary, Klinowska, Teresa, primary, Pike, Kurt G., primary, Pass, Martin, primary, Chresta, Christine M., primary, Polanska, Urszula M., primary, McEwen, Robert, primary, Delpuech, Oona, primary, Green, Stephen, primary, and Cosulich, Sabina C., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Tables 1 through 4 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Author

Guichard, Sylvie M., primary, Curwen, Jon, primary, Bihani, Teeru, primary, D'Cruz, Celina M., primary, Yates, James W.T., primary, Grondine, Michael, primary, Howard, Zoe, primary, Davies, Barry R., primary, Bigley, Graham, primary, Klinowska, Teresa, primary, Pike, Kurt G., primary, Pass, Martin, primary, Chresta, Christine M., primary, Polanska, Urszula M., primary, McEwen, Robert, primary, Delpuech, Oona, primary, Green, Stephen, primary, and Cosulich, Sabina C., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure Legends 1-5 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Author

Davies, Barry R., primary, Greenwood, Hannah, primary, Dudley, Phillippa, primary, Crafter, Claire, primary, Yu, De-Hua, primary, Zhang, Jingchuan, primary, Li, Jing, primary, Gao, Beirong, primary, Ji, Qunsheng, primary, Maynard, Juliana, primary, Ricketts, Sally-Ann, primary, Cross, Darren, primary, Cosulich, Sabina, primary, Chresta, Christine C., primary, Page, Ken, primary, Yates, James, primary, Lane, Clare, primary, Watson, Rebecca, primary, Luke, Richard, primary, Ogilvie, Donald, primary, and Pass, Martin, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 1 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Author

Davies, Barry R., primary, Greenwood, Hannah, primary, Dudley, Phillippa, primary, Crafter, Claire, primary, Yu, De-Hua, primary, Zhang, Jingchuan, primary, Li, Jing, primary, Gao, Beirong, primary, Ji, Qunsheng, primary, Maynard, Juliana, primary, Ricketts, Sally-Ann, primary, Cross, Darren, primary, Cosulich, Sabina, primary, Chresta, Christine C., primary, Page, Ken, primary, Yates, James, primary, Lane, Clare, primary, Watson, Rebecca, primary, Luke, Richard, primary, Ogilvie, Donald, primary, and Pass, Martin, primary

Published
2023
Full Text
View/download PDF

9. Supplementary figure 1 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Author

Guichard, Sylvie M., primary, Curwen, Jon, primary, Bihani, Teeru, primary, D'Cruz, Celina M., primary, Yates, James W.T., primary, Grondine, Michael, primary, Howard, Zoe, primary, Davies, Barry R., primary, Bigley, Graham, primary, Klinowska, Teresa, primary, Pike, Kurt G., primary, Pass, Martin, primary, Chresta, Christine M., primary, Polanska, Urszula M., primary, McEwen, Robert, primary, Delpuech, Oona, primary, Green, Stephen, primary, and Cosulich, Sabina C., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 1 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Author

Davies, Barry R., primary, Greenwood, Hannah, primary, Dudley, Phillippa, primary, Crafter, Claire, primary, Yu, De-Hua, primary, Zhang, Jingchuan, primary, Li, Jing, primary, Gao, Beirong, primary, Ji, Qunsheng, primary, Maynard, Juliana, primary, Ricketts, Sally-Ann, primary, Cross, Darren, primary, Cosulich, Sabina, primary, Chresta, Christine C., primary, Page, Ken, primary, Yates, James, primary, Lane, Clare, primary, Watson, Rebecca, primary, Luke, Richard, primary, Ogilvie, Donald, primary, and Pass, Martin, primary

Published
2023
Full Text
View/download PDF

11. Data from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Author

Karlin, Jeremy, primary, Allen, Jasmine, primary, Ahmad, Syed F., primary, Hughes, Gareth, primary, Sheridan, Victoria, primary, Odedra, Rajesh, primary, Farrington, Paul, primary, Cadogan, Elaine B., primary, Riches, Lucy C., primary, Garcia-Trinidad, Antonio, primary, Thomason, Andrew G., primary, Patel, Bhavika, primary, Vincent, Jennifer, primary, Lau, Alan, primary, Pike, Kurt G., primary, Hunt, Thomas A., primary, Sule, Amrita, primary, Valerie, Nicholas C.K., primary, Biddlestone-Thorpe, Laura, primary, Kahn, Jenna, primary, Beckta, Jason M., primary, Mukhopadhyay, Nitai, primary, Barlaam, Bernard, primary, Degorce, Sebastien L., primary, Kettle, Jason, primary, Colclough, Nicola, primary, Wilson, Joanne, primary, Smith, Aaron, primary, Barrett, Ian P., primary, Zheng, Li, primary, Zhang, Tianwei, primary, Wang, Yingchun, primary, Chen, Kan, primary, Pass, Martin, primary, Durant, Stephen T., primary, and Valerie, Kristoffer, primary

Published
2023
Full Text
View/download PDF

12. Supplementary methods from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Author

Guichard, Sylvie M., primary, Curwen, Jon, primary, Bihani, Teeru, primary, D'Cruz, Celina M., primary, Yates, James W.T., primary, Grondine, Michael, primary, Howard, Zoe, primary, Davies, Barry R., primary, Bigley, Graham, primary, Klinowska, Teresa, primary, Pike, Kurt G., primary, Pass, Martin, primary, Chresta, Christine M., primary, Polanska, Urszula M., primary, McEwen, Robert, primary, Delpuech, Oona, primary, Green, Stephen, primary, and Cosulich, Sabina C., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Information from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Author

Karlin, Jeremy, primary, Allen, Jasmine, primary, Ahmad, Syed F., primary, Hughes, Gareth, primary, Sheridan, Victoria, primary, Odedra, Rajesh, primary, Farrington, Paul, primary, Cadogan, Elaine B., primary, Riches, Lucy C., primary, Garcia-Trinidad, Antonio, primary, Thomason, Andrew G., primary, Patel, Bhavika, primary, Vincent, Jennifer, primary, Lau, Alan, primary, Pike, Kurt G., primary, Hunt, Thomas A., primary, Sule, Amrita, primary, Valerie, Nicholas C.K., primary, Biddlestone-Thorpe, Laura, primary, Kahn, Jenna, primary, Beckta, Jason M., primary, Mukhopadhyay, Nitai, primary, Barlaam, Bernard, primary, Degorce, Sebastien L., primary, Kettle, Jason, primary, Colclough, Nicola, primary, Wilson, Joanne, primary, Smith, Aaron, primary, Barrett, Ian P., primary, Zheng, Li, primary, Zhang, Tianwei, primary, Wang, Yingchun, primary, Chen, Kan, primary, Pass, Martin, primary, Durant, Stephen T., primary, and Valerie, Kristoffer, primary

Published
2023
Full Text
View/download PDF

14. Video 2 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Author

Karlin, Jeremy, primary, Allen, Jasmine, primary, Ahmad, Syed F., primary, Hughes, Gareth, primary, Sheridan, Victoria, primary, Odedra, Rajesh, primary, Farrington, Paul, primary, Cadogan, Elaine B., primary, Riches, Lucy C., primary, Garcia-Trinidad, Antonio, primary, Thomason, Andrew G., primary, Patel, Bhavika, primary, Vincent, Jennifer, primary, Lau, Alan, primary, Pike, Kurt G., primary, Hunt, Thomas A., primary, Sule, Amrita, primary, Valerie, Nicholas C.K., primary, Biddlestone-Thorpe, Laura, primary, Kahn, Jenna, primary, Beckta, Jason M., primary, Mukhopadhyay, Nitai, primary, Barlaam, Bernard, primary, Degorce, Sebastien L., primary, Kettle, Jason, primary, Colclough, Nicola, primary, Wilson, Joanne, primary, Smith, Aaron, primary, Barrett, Ian P., primary, Zheng, Li, primary, Zhang, Tianwei, primary, Wang, Yingchun, primary, Chen, Kan, primary, Pass, Martin, primary, Durant, Stephen T., primary, and Valerie, Kristoffer, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 2 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Author

Davies, Barry R., primary, Greenwood, Hannah, primary, Dudley, Phillippa, primary, Crafter, Claire, primary, Yu, De-Hua, primary, Zhang, Jingchuan, primary, Li, Jing, primary, Gao, Beirong, primary, Ji, Qunsheng, primary, Maynard, Juliana, primary, Ricketts, Sally-Ann, primary, Cross, Darren, primary, Cosulich, Sabina, primary, Chresta, Christine C., primary, Page, Ken, primary, Yates, James, primary, Lane, Clare, primary, Watson, Rebecca, primary, Luke, Richard, primary, Ogilvie, Donald, primary, and Pass, Martin, primary

Published
2023
Full Text
View/download PDF

16. Video 3 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Author

Karlin, Jeremy, primary, Allen, Jasmine, primary, Ahmad, Syed F., primary, Hughes, Gareth, primary, Sheridan, Victoria, primary, Odedra, Rajesh, primary, Farrington, Paul, primary, Cadogan, Elaine B., primary, Riches, Lucy C., primary, Garcia-Trinidad, Antonio, primary, Thomason, Andrew G., primary, Patel, Bhavika, primary, Vincent, Jennifer, primary, Lau, Alan, primary, Pike, Kurt G., primary, Hunt, Thomas A., primary, Sule, Amrita, primary, Valerie, Nicholas C.K., primary, Biddlestone-Thorpe, Laura, primary, Kahn, Jenna, primary, Beckta, Jason M., primary, Mukhopadhyay, Nitai, primary, Barlaam, Bernard, primary, Degorce, Sebastien L., primary, Kettle, Jason, primary, Colclough, Nicola, primary, Wilson, Joanne, primary, Smith, Aaron, primary, Barrett, Ian P., primary, Zheng, Li, primary, Zhang, Tianwei, primary, Wang, Yingchun, primary, Chen, Kan, primary, Pass, Martin, primary, Durant, Stephen T., primary, and Valerie, Kristoffer, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 3 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Author

Davies, Barry R., primary, Greenwood, Hannah, primary, Dudley, Phillippa, primary, Crafter, Claire, primary, Yu, De-Hua, primary, Zhang, Jingchuan, primary, Li, Jing, primary, Gao, Beirong, primary, Ji, Qunsheng, primary, Maynard, Juliana, primary, Ricketts, Sally-Ann, primary, Cross, Darren, primary, Cosulich, Sabina, primary, Chresta, Christine C., primary, Page, Ken, primary, Yates, James, primary, Lane, Clare, primary, Watson, Rebecca, primary, Luke, Richard, primary, Ogilvie, Donald, primary, and Pass, Martin, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 5 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Author

Davies, Barry R., primary, Greenwood, Hannah, primary, Dudley, Phillippa, primary, Crafter, Claire, primary, Yu, De-Hua, primary, Zhang, Jingchuan, primary, Li, Jing, primary, Gao, Beirong, primary, Ji, Qunsheng, primary, Maynard, Juliana, primary, Ricketts, Sally-Ann, primary, Cross, Darren, primary, Cosulich, Sabina, primary, Chresta, Christine C., primary, Page, Ken, primary, Yates, James, primary, Lane, Clare, primary, Watson, Rebecca, primary, Luke, Richard, primary, Ogilvie, Donald, primary, and Pass, Martin, primary

Published
2023
Full Text
View/download PDF

19. Supplementary figure 4 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Author

Guichard, Sylvie M., primary, Curwen, Jon, primary, Bihani, Teeru, primary, D'Cruz, Celina M., primary, Yates, James W.T., primary, Grondine, Michael, primary, Howard, Zoe, primary, Davies, Barry R., primary, Bigley, Graham, primary, Klinowska, Teresa, primary, Pike, Kurt G., primary, Pass, Martin, primary, Chresta, Christine M., primary, Polanska, Urszula M., primary, McEwen, Robert, primary, Delpuech, Oona, primary, Green, Stephen, primary, and Cosulich, Sabina C., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 4 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Author

Davies, Barry R., primary, Greenwood, Hannah, primary, Dudley, Phillippa, primary, Crafter, Claire, primary, Yu, De-Hua, primary, Zhang, Jingchuan, primary, Li, Jing, primary, Gao, Beirong, primary, Ji, Qunsheng, primary, Maynard, Juliana, primary, Ricketts, Sally-Ann, primary, Cross, Darren, primary, Cosulich, Sabina, primary, Chresta, Christine C., primary, Page, Ken, primary, Yates, James, primary, Lane, Clare, primary, Watson, Rebecca, primary, Luke, Richard, primary, Ogilvie, Donald, primary, and Pass, Martin, primary

Published
2023
Full Text
View/download PDF

21. Supplementary figure 3 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Author

Guichard, Sylvie M., primary, Curwen, Jon, primary, Bihani, Teeru, primary, D'Cruz, Celina M., primary, Yates, James W.T., primary, Grondine, Michael, primary, Howard, Zoe, primary, Davies, Barry R., primary, Bigley, Graham, primary, Klinowska, Teresa, primary, Pike, Kurt G., primary, Pass, Martin, primary, Chresta, Christine M., primary, Polanska, Urszula M., primary, McEwen, Robert, primary, Delpuech, Oona, primary, Green, Stephen, primary, and Cosulich, Sabina C., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

Author

Robertson, John F.R., primary, Coleman, Robert E., primary, Cheung, Kwok-Leung, primary, Evans, Abigail, primary, Holcombe, Chris, primary, Skene, Anthony, primary, Rea, Daniel, primary, Ahmed, Samreen, primary, Jahan, Ali, primary, Horgan, Kieran, primary, Rauchhaus, Petra, primary, Littleford, Roberta, primary, Cheung, S.Y. Amy, primary, Cullberg, Marie, primary, de Bruin, Elza C., primary, Koulai, Loumpiana, primary, Lindemann, Justin P.O., primary, Pass, Martin, primary, Rugman, Paul, primary, Schiavon, Gaia, primary, Deb, Rahul, primary, Finlay, Pauline, primary, Foxley, Andrew, primary, and Gee, Julia M.W., primary

Published
2023
Full Text
View/download PDF

23. Supplementary material from A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

Author

Banerji, Udai, primary, Dean, Emma J., primary, Pérez-Fidalgo, J. Alejandro, primary, Batist, Gerald, primary, Bedard, Philippe L., primary, You, Benoit, primary, Westin, Shannon N., primary, Kabos, Peter, primary, Garrett, Michelle D., primary, Tall, Mathew, primary, Ambrose, Helen, primary, Barrett, J. Carl, primary, Carr, T. Hedley, primary, Cheung, S.Y. Amy, primary, Corcoran, Claire, primary, Cullberg, Marie, primary, Davies, Barry R., primary, de Bruin, Elza C., primary, Elvin, Paul, primary, Foxley, Andrew, primary, Lawrence, Peter, primary, Lindemann, Justin P.O., primary, Maudsley, Rhiannon, primary, Pass, Martin, primary, Rowlands, Vicky, primary, Rugman, Paul, primary, Schiavon, Gaia, primary, Yates, James, primary, and Schellens, Jan H.M., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 3 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Author

Smyth, Lillian M., primary, Tamura, Kenji, primary, Oliveira, Mafalda, primary, Ciruelos, Eva M., primary, Mayer, Ingrid A., primary, Sablin, Marie-Paule, primary, Biganzoli, Laura, primary, Ambrose, Helen J., primary, Ashton, Jack, primary, Barnicle, Alan, primary, Cashell, Des D., primary, Corcoran, Claire, primary, de Bruin, Elza C., primary, Foxley, Andrew, primary, Hauser, Joana, primary, Lindemann, Justin P.O., primary, Maudsley, Rhiannon, primary, McEwen, Robert, primary, Moschetta, Michele, primary, Pass, Martin, primary, Rowlands, Vicky, primary, Schiavon, Gaia, primary, Banerji, Udai, primary, Scaltriti, Maurizio, primary, Taylor, Barry S., primary, Chandarlapaty, Sarat, primary, Baselga, José, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 1 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Author

Smyth, Lillian M., primary, Tamura, Kenji, primary, Oliveira, Mafalda, primary, Ciruelos, Eva M., primary, Mayer, Ingrid A., primary, Sablin, Marie-Paule, primary, Biganzoli, Laura, primary, Ambrose, Helen J., primary, Ashton, Jack, primary, Barnicle, Alan, primary, Cashell, Des D., primary, Corcoran, Claire, primary, de Bruin, Elza C., primary, Foxley, Andrew, primary, Hauser, Joana, primary, Lindemann, Justin P.O., primary, Maudsley, Rhiannon, primary, McEwen, Robert, primary, Moschetta, Michele, primary, Pass, Martin, primary, Rowlands, Vicky, primary, Schiavon, Gaia, primary, Banerji, Udai, primary, Scaltriti, Maurizio, primary, Taylor, Barry S., primary, Chandarlapaty, Sarat, primary, Baselga, José, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 2 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Author

Smyth, Lillian M., primary, Tamura, Kenji, primary, Oliveira, Mafalda, primary, Ciruelos, Eva M., primary, Mayer, Ingrid A., primary, Sablin, Marie-Paule, primary, Biganzoli, Laura, primary, Ambrose, Helen J., primary, Ashton, Jack, primary, Barnicle, Alan, primary, Cashell, Des D., primary, Corcoran, Claire, primary, de Bruin, Elza C., primary, Foxley, Andrew, primary, Hauser, Joana, primary, Lindemann, Justin P.O., primary, Maudsley, Rhiannon, primary, McEwen, Robert, primary, Moschetta, Michele, primary, Pass, Martin, primary, Rowlands, Vicky, primary, Schiavon, Gaia, primary, Banerji, Udai, primary, Scaltriti, Maurizio, primary, Taylor, Barry S., primary, Chandarlapaty, Sarat, primary, Baselga, José, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table 4 from A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

Author

Banerji, Udai, primary, Dean, Emma J., primary, Pérez-Fidalgo, J. Alejandro, primary, Batist, Gerald, primary, Bedard, Philippe L., primary, You, Benoit, primary, Westin, Shannon N., primary, Kabos, Peter, primary, Garrett, Michelle D., primary, Tall, Mathew, primary, Ambrose, Helen, primary, Barrett, J. Carl, primary, Carr, T. Hedley, primary, Cheung, S.Y. Amy, primary, Corcoran, Claire, primary, Cullberg, Marie, primary, Davies, Barry R., primary, de Bruin, Elza C., primary, Elvin, Paul, primary, Foxley, Andrew, primary, Lawrence, Peter, primary, Lindemann, Justin P.O., primary, Maudsley, Rhiannon, primary, Pass, Martin, primary, Rowlands, Vicky, primary, Rugman, Paul, primary, Schiavon, Gaia, primary, Yates, James, primary, and Schellens, Jan H.M., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Material from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Author

Smyth, Lillian M., primary, Tamura, Kenji, primary, Oliveira, Mafalda, primary, Ciruelos, Eva M., primary, Mayer, Ingrid A., primary, Sablin, Marie-Paule, primary, Biganzoli, Laura, primary, Ambrose, Helen J., primary, Ashton, Jack, primary, Barnicle, Alan, primary, Cashell, Des D., primary, Corcoran, Claire, primary, de Bruin, Elza C., primary, Foxley, Andrew, primary, Hauser, Joana, primary, Lindemann, Justin P.O., primary, Maudsley, Rhiannon, primary, McEwen, Robert, primary, Moschetta, Michele, primary, Pass, Martin, primary, Rowlands, Vicky, primary, Schiavon, Gaia, primary, Banerji, Udai, primary, Scaltriti, Maurizio, primary, Taylor, Barry S., primary, Chandarlapaty, Sarat, primary, Baselga, José, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table 1 from AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

Author

Chresta, Christine M., primary, Davies, Barry R., primary, Hickson, Ian, primary, Harding, Tom, primary, Cosulich, Sabina, primary, Critchlow, Susan E., primary, Vincent, John P., primary, Ellston, Rebecca, primary, Jones, Darren, primary, Sini, Patrizia, primary, James, Dominic, primary, Howard, Zoe, primary, Dudley, Phillippa, primary, Hughes, Gareth, primary, Smith, Lisa, primary, Maguire, Sharon, primary, Hummersone, Marc, primary, Malagu, Karine, primary, Menear, Keith, primary, Jenkins, Richard, primary, Jacobsen, Matt, primary, Smith, Graeme C.M., primary, Guichard, Sylvie, primary, and Pass, Martin, primary

Published
2023
Full Text
View/download PDF

30. Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

Author

Robertson, John F.R., primary, Coleman, Robert E., additional, Cheung, Kwok-Leung, additional, Evans, Abigail, additional, Holcombe, Chris, additional, Skene, Anthony, additional, Rea, Daniel, additional, Ahmed, Samreen, additional, Jahan, Ali, additional, Horgan, Kieran, additional, Rauchhaus, Petra, additional, Littleford, Roberta, additional, Amy Cheung, S.Y., additional, Cullberg, Marie, additional, de Bruin, Elza C., additional, Koulai, Loumpiana, additional, Lindemann, Justin P.O., additional, Pass, Martin, additional, Rugman, Paul, additional, Schiavon, Gaia, additional, Deb, Rahul, additional, Finlay, Pauline, additional, Foxley, Andrew, additional, and Gee, Julia M.W., additional

Published
2022
Full Text
View/download PDF

32. Brain exposure of the ATM inhibitor AZD1390 in humans—a positron emission tomography study

Author

Jucaite, Aurelija, primary, Stenkrona, Per, additional, Cselényi, Zsolt, additional, De Vita, Serena, additional, Buil-Bruna, Nuria, additional, Varnäs, Katarina, additional, Savage, Alicia, additional, Varrone, Andrea, additional, Johnström, Peter, additional, Schou, Magnus, additional, Davison, Chris, additional, Sykes, Andy, additional, Pilla Reddy, Venkatesh, additional, Hoch, Matthias, additional, Vazquez-Romero, Ana, additional, Moein, Mohammad Mahdi, additional, Halldin, Christer, additional, Merchant, Melinda S, additional, Pass, Martin, additional, and Farde, Lars, additional

Published
2020
Full Text
View/download PDF

33. Abstract 6168: Characterization of ATM inhibitor (AZD1390) distribution and pharmacodynamic changes in brain and glioblastoma in preclinical models to inform on mechanism of action

Author

Oplustil O'Connor, Lenka, primary, Hamm, Gregory, additional, Udriste, Maria, additional, Ling, Stephanie, additional, Wilson, Joanne, additional, Durant, Steve, additional, Hughes, Gareth, additional, Cosulich, Sabina, additional, Shao, Wenlin, additional, Pass, Martin, additional, Jones, Gemma, additional, Pierce, Andrew, additional, Goodwin, Richard, additional, O'Connor, Mark, additional, Barrett, Carl, additional, and Harrington, Elizabeth, additional

Published
2020
Full Text
View/download PDF

34. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients withAKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Author

Smyth, Lillian M., primary, Tamura, Kenji, additional, Oliveira, Mafalda, additional, Ciruelos, Eva M., additional, Mayer, Ingrid A., additional, Sablin, Marie-Paule, additional, Biganzoli, Laura, additional, Ambrose, Helen J., additional, Ashton, Jack, additional, Barnicle, Alan, additional, Cashell, Des D., additional, Corcoran, Claire, additional, de Bruin, Elza C., additional, Foxley, Andrew, additional, Hauser, Joana, additional, Lindemann, Justin P.O., additional, Maudsley, Rhiannon, additional, McEwen, Robert, additional, Moschetta, Michele, additional, Pass, Martin, additional, Rowlands, Vicky, additional, Schiavon, Gaia, additional, Banerji, Udai, additional, Scaltriti, Maurizio, additional, Taylor, Barry S., additional, Chandarlapaty, Sarat, additional, Baselga, José, additional, and Hyman, David M., additional

Published
2020
Full Text
View/download PDF

35. Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically

Author

Riches, Lucy C., primary, Trinidad, Antonio G., additional, Hughes, Gareth, additional, Jones, Gemma N., additional, Hughes, Adina M., additional, Thomason, Andrew G., additional, Gavine, Paul, additional, Cui, Andy, additional, Ling, Stephanie, additional, Stott, Jonathan, additional, Clark, Roger, additional, Peel, Samantha, additional, Gill, Pendeep, additional, Goodwin, Louise M., additional, Smith, Aaron, additional, Pike, Kurt G., additional, Barlaam, Bernard, additional, Pass, Martin, additional, O'Connor, Mark J., additional, Smith, Graeme, additional, and Cadogan, Elaine B., additional

Published
2020
Full Text
View/download PDF

36. Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

Author

Robertson, John F.R., primary, Coleman, Robert E., additional, Cheung, Kwok-Leung, additional, Evans, Abigail, additional, Holcombe, Chris, additional, Skene, Anthony, additional, Rea, Daniel, additional, Ahmed, Samreen, additional, Jahan, Ali, additional, Horgan, Kieran, additional, Rauchhaus, Petra, additional, Littleford, Roberta, additional, Cheung, S.Y. Amy, additional, Cullberg, Marie, additional, de Bruin, Elza C., additional, Koulai, Loumpiana, additional, Lindemann, Justin P.O., additional, Pass, Martin, additional, Rugman, Paul, additional, Schiavon, Gaia, additional, Deb, Rahul, additional, Finlay, Pauline, additional, Foxley, Andrew, additional, and Gee, Julia M.W., additional

Published
2019
Full Text
View/download PDF

37. A phase i open-label study to identify a dosing regimen of the pan-akt inhibitor azd5363 for evaluation in solid tumors and in pik3ca-mutated breast and gynecologic cancers

Author

Banerji, Udai, Dean, Emma J, Pérez-Fidalgo, J Alejandro, Batist, Gerald, Bedard, Philippe L, You, Benoit, Westin, Shannon N, Kabos, Peter, Garrett, Michelle D, Tall, Mathew, Ambrose, Helen, Barrett, J Carl, Carr, T Hedley, Cheung, S Y Amy, Corcoran, Claire, Cullberg, Marie, Davies, Barry R, de Bruin, Elza C, Elvin, Paul, Foxley, Andrew, Lawrence, Peter, Lindemann, Justin P O, Maudsley, Rhiannon, Pass, Martin, Rowlands, Vicky, Rugman, Paul, Schiavon, Gaia, Yates, James, Schellens, Jan H M, Afd Pharmacoepi & Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Performance status, Manchester Cancer Research Centre, business.industry, Nausea, ResearchInstitutes_Networks_Beacons/mcrc, Common Terminology Criteria for Adverse Events, Rash, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Tolerability, 030220 oncology & carcinogenesis, Internal medicine, Pharmacodynamics, Medicine, Dosing, medicine.symptom, business, Adverse effect
Abstract

Purpose: This phase I, open-label study (Study 1, D3610C00001; NCT01226316) was the first-in-human evaluation of oral AZD5363, a selective pan-AKT inhibitor, in patients with advanced solid malignancies. The objectives were to investigate the safety, tolerability, and pharmacokinetics of AZD5363, define a recommended dosing schedule, and evaluate preliminary clinical activity. Experimental Design: Patients were aged ≥18 years with World Health Organization (WHO) performance status of 0 to 1. Dose escalation was conducted within separate continuous and intermittent [4 days/week (4/7) or 2 days/week (2/7)] schedules with safety, pharmacokinetic, and pharmacodynamic analyses. Expansion cohorts of approximately 20 patients each explored AZD5363 activity in PIK3CA-mutant breast and gynecologic cancers. Results: MTDs were 320, 480, and 640 mg for continuous (n = 47), 4/7 (n = 21), and 2/7 (n = 22) schedules, respectively. Dose-limiting toxicities were rash and diarrhea for continuous, hyperglycemia for 2/7, and none for 4/7. Common adverse events were diarrhea (78%) and nausea (49%) and, for Common Terminology Criteria for Adverse Events grade ≥3 events, hyperglycemia (20%). The recommended phase II dose (480 mg bid, 4/7 intermittent) was assessed in PIK3CA-mutant breast and gynecologic expansion cohorts: 46% and 56% of patients, respectively, showed a reduction in tumor size, with RECIST responses of 4% and 8%. These responses were less than the prespecified 20% response rate; therefore, the criteria to stop further recruitment to the PIK3CA-mutant cohort were met. Conclusions: At the recommended phase II dose, AZD5363 was well tolerated and achieved plasma levels and robust target modulation in tumors. Proof-of-concept responses were observed in patients with PIK3CA-mutant cancers treated with AZD5363. Clin Cancer Res; 24(9); 2050–9. ©2017 AACR. See related commentary by Costa and Bosch, p. 2029

Published
2018

38. Abstract 4868: A preclinical PK/PD model based on a mouse glioblastoma survival model for AZD1390, a novel, brain-penetrant ATM kinase inhibitor, to predict the inhibition of DNA damage response induced by radiation and the human efficacious dose

Author

Reddy, Venkatesh Pilla, primary, Sykes, Andy, additional, Colclough, Nicola, additional, Durant, Stephen T., additional, O'Connor, Lenka Oplustil, additional, Hoch, Matthias, additional, Bruna, Nuria Buil, additional, Vita, Serena De, additional, Merchant, Melinda, additional, and Pass, Martin, additional

Published
2019
Full Text
View/download PDF

39. Brain exposure of the ATM inhibitor AZD1390 in humans—a positron emission tomography study.

Author

Jucaite, Aurelija, Stenkrona, Per, Cselényi, Zsolt, Vita, Serena De, Buil-Bruna, Nuria, Varnäs, Katarina, Savage, Alicia, Varrone, Andrea, Johnström, Peter, Schou, Magnus, Davison, Chris, Sykes, Andy, Reddy, Venkatesh Pilla, Hoch, Matthias, Vazquez-Romero, Ana, Moein, Mohammad Mahdi, Halldin, Christer, Merchant, Melinda S, Pass, Martin, and Farde, Lars

Published
2021
Full Text
View/download PDF

40. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Banerji, Udai, Dean, Emma J, Pérez-Fidalgo, J Alejandro, Batist, Gerald, Bedard, Philippe L, You, Benoit, Westin, Shannon N, Kabos, Peter, Garrett, Michelle D, Tall, Mathew, Ambrose, Helen, Barrett, J Carl, Carr, T Hedley, Cheung, S Y Amy, Corcoran, Claire, Cullberg, Marie, Davies, Barry R, de Bruin, Elza C, Elvin, Paul, Foxley, Andrew, Lawrence, Peter, Lindemann, Justin P O, Maudsley, Rhiannon, Pass, Martin, Rowlands, Vicky, Rugman, Paul, Schiavon, Gaia, Yates, James, Schellens, Jan H M, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Banerji, Udai, Dean, Emma J, Pérez-Fidalgo, J Alejandro, Batist, Gerald, Bedard, Philippe L, You, Benoit, Westin, Shannon N, Kabos, Peter, Garrett, Michelle D, Tall, Mathew, Ambrose, Helen, Barrett, J Carl, Carr, T Hedley, Cheung, S Y Amy, Corcoran, Claire, Cullberg, Marie, Davies, Barry R, de Bruin, Elza C, Elvin, Paul, Foxley, Andrew, Lawrence, Peter, Lindemann, Justin P O, Maudsley, Rhiannon, Pass, Martin, Rowlands, Vicky, Rugman, Paul, Schiavon, Gaia, Yates, James, and Schellens, Jan H M

Published
2018

41. A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers

Author

Banerji, Udai, Dean, Emma J., Pérez-Fidalgo, J. Alejandro, Batist, Gerald, Bedard, Philippe L., You, Benoit, Westin, Shannon N., Kabos, Peter, Garrett, Michelle D., Tall, Mathew, Ambrose, Helen, Barrett, J. Carl, Carr, T. Hedley, Cheung, S.Y. Amy, Corcoran, Claire, Cullberg, Marie, Davies, Barry R., de Bruin, Elza C., Elvin, Paul, Foxley, Andrew, Lawrence, Peter, Lindemann, Justin P.O., Maudsley, Rhiannon, Pass, Martin, Rowlands, Vicky, Rugman, Paul, Schiavon, Gaia, Yates, James, and Schellens, Jan H.M.

Abstract

Purpose: This Phase 1, open-label study (Study 1, D3610C00001; NCT01226316) was the first-in-human evaluation of oral AZD5363, a selective pan-AKT inhibitor, in patients with advanced solid malignancies. The objectives were to investigate the safety, tolerability and pharmacokinetics of AZD5363, define a recommended dosing schedule, and evaluate preliminary clinical activity.\ud \ud Experimental design: Patients were aged ?18 years with WHO performance status 0–1. Dose escalation was conducted within separate continuous and intermittent (4 days/week [4/7] or 2 days/week [2/7]) schedules with safety, pharmacokinetic and pharmacodynamic analyses. Expansion cohorts of approximately 20 patients each explored AZD5363 activity in PIK3CA-mutant breast and gynecologic cancers.\ud \ud Results: Maximum tolerated doses were 320 mg, 480 mg and 640 mg for continuous (n=47), 4/7 (n=21) and 2/7 (n=22) schedules, respectively. Dose-limiting toxicities were rash and diarrhea for continuous, hyperglycemia for 2/7, and none for 4/7. Common adverse events were diarrhea (78%) and nausea (49%) and, for CTCAE grade ?3 events, hyperglycemia (20%). The recommended Phase 2 dose (480 mg bid, 4/7 intermittent) was assessed in PIK3CA-mutant breast and gynecologic expansion cohorts: 46% and 56% of patients, respectively, showed a reduction in tumor size, with RECIST responses of 4% and 8%. These responses were less than the pre-specified 20% response rate; therefore, the criteria to stop further recruitment to the PIK3CA cohort were met.\ud \ud Conclusions: At the recommended Phase 2 dose, AZD5363 was well tolerated and achieved plasma levels and robust target modulation in tumors. Proof-of-concept responses were observed in patients with PIK3CA-mutant cancers treated with AZD5363.

Published
2017

42. Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Author

Karlin, Jeremy, primary, Allen, Jasmine, additional, Ahmad, Syed F., additional, Hughes, Gareth, additional, Sheridan, Victoria, additional, Odedra, Rajesh, additional, Farrington, Paul, additional, Cadogan, Elaine B., additional, Riches, Lucy C., additional, Garcia-Trinidad, Antonio, additional, Thomason, Andrew G., additional, Patel, Bhavika, additional, Vincent, Jennifer, additional, Lau, Alan, additional, Pike, Kurt G., additional, Hunt, Thomas A., additional, Sule, Amrita, additional, Valerie, Nicholas C.K., additional, Biddlestone-Thorpe, Laura, additional, Kahn, Jenna, additional, Beckta, Jason M., additional, Mukhopadhyay, Nitai, additional, Barlaam, Bernard, additional, Degorce, Sebastien L., additional, Kettle, Jason, additional, Colclough, Nicola, additional, Wilson, Joanne, additional, Smith, Aaron, additional, Barrett, Ian P., additional, Zheng, Li, additional, Zhang, Tianwei, additional, Wang, Yingchun, additional, Chen, Kan, additional, Pass, Martin, additional, Durant, Stephen T., additional, and Valerie, Kristoffer, additional

Published
2018
Full Text
View/download PDF

43. Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors

Author

Barlaam, Bernard, primary, Cadogan, Elaine, additional, Campbell, Andrew, additional, Colclough, Nicola, additional, Dishington, Allan, additional, Durant, Stephen, additional, Goldberg, Kristin, additional, Hassall, Lorraine A., additional, Hughes, Gareth D., additional, MacFaul, Philip A., additional, McGuire, Thomas M., additional, Pass, Martin, additional, Patel, Anil, additional, Pearson, Stuart, additional, Petersen, Jens, additional, Pike, Kurt G., additional, Robb, Graeme, additional, Stratton, Natalie, additional, Xin, Guohong, additional, and Zhai, Baochang, additional

Published
2018
Full Text
View/download PDF

45. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

Author

Durant, Stephen T., primary, Zheng, Li, additional, Wang, Yingchun, additional, Chen, Kan, additional, Zhang, Lingli, additional, Zhang, Tianwei, additional, Yang, Zhenfan, additional, Riches, Lucy, additional, Trinidad, Antonio G., additional, Fok, Jacqueline H. L., additional, Hunt, Tom, additional, Pike, Kurt G., additional, Wilson, Joanne, additional, Smith, Aaron, additional, Colclough, Nicola, additional, Reddy, Venkatesh Pilla, additional, Sykes, Andrew, additional, Janefeldt, Annika, additional, Johnström, Peter, additional, Varnäs, Katarina, additional, Takano, Akihiro, additional, Ling, Stephanie, additional, Orme, Jonathan, additional, Stott, Jonathan, additional, Roberts, Caroline, additional, Barrett, Ian, additional, Jones, Gemma, additional, Roudier, Martine, additional, Pierce, Andrew, additional, Allen, Jasmine, additional, Kahn, Jenna, additional, Sule, Amrita, additional, Karlin, Jeremy, additional, Cronin, Anna, additional, Chapman, Melissa, additional, Valerie, Kristoffer, additional, Illingworth, Ruth, additional, and Pass, Martin, additional

Published
2018
Full Text
View/download PDF

46. The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one)

Author

Pike, Kurt G., primary, Barlaam, Bernard, additional, Cadogan, Elaine, additional, Campbell, Andrew, additional, Chen, Yingxue, additional, Colclough, Nicola, additional, Davies, Nichola L., additional, de-Almeida, Camila, additional, Degorce, Sebastien L., additional, Didelot, Myriam, additional, Dishington, Allan, additional, Ducray, Richard, additional, Durant, Stephen T., additional, Hassall, Lorraine A., additional, Holmes, Jane, additional, Hughes, Gareth D., additional, MacFaul, Philip A., additional, Mulholland, Keith R., additional, McGuire, Thomas M., additional, Ouvry, Gilles, additional, Pass, Martin, additional, Robb, Graeme, additional, Stratton, Natalie, additional, Wang, Zhenhua, additional, Wilson, Joanne, additional, Zhai, Baochang, additional, Zhao, Kang, additional, and Al-Huniti, Nidal, additional

Published
2018
Full Text
View/download PDF

47. Abstract A104: AZD1390, a potent and selective orally bioavailable blood-brain barrier-penetrant ATM inhibitor, radiosensitizes and improves survival of orthotopic glioma and metastatic brain tumor models

Author

Durant, Steve T., primary, Pike, Kurt G., additional, Colclough, Nicola, additional, Riches, Lucy, additional, Garcia-Trinidad, Antonio, additional, Hunt, Thomas, additional, Ling, Stephanie, additional, Stott, Jonathan, additional, Barrett, Ian, additional, Zheng, Li, additional, Wang, Yingchun, additional, Chen, Kan, additional, Zhang, Tianwei, additional, Pilla Reddy, Venkatesh, additional, Sykes, Andrew, additional, Johnstrom, Peter, additional, Jones, Gemma, additional, Pierce, Andrew, additional, Karlin, Jeremy, additional, Kahn, Jenna, additional, Allen, Jasmine, additional, Valerie, Kristoffer, additional, Illingworth, Ruth, additional, and Pass, Martin, additional

Published
2018
Full Text
View/download PDF

48. Abstract A094: Phase I modular study of AZD0156, a first-in-class oral selective inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with olaparib (AToM Study, Module 1)

Author

Abida, Wassim, primary, Bang, Yung J., additional, Carter, Louise, additional, Azaro, Analía, additional, Krebs, Matthew, additional, Im, Seock-Ah, additional, Chen, Yingxue, additional, Buil-Bruna, Núria, additional, Li, Yan, additional, Eaton, David, additional, Stephens, Christine, additional, Ross, Graham, additional, Pass, Martin, additional, Rodon, Jordi, additional, and Dean, Emma, additional

Published
2018
Full Text
View/download PDF

49. Thrombin inhibitors based on [5,5] trans-fused indane lactams

Author

Pass, Martin, Abu-Rabie, Said, Baxter, Andrew, Conroy, Richard, Coote, Steven J, Craven, Andrew P, Finch, Harry, Hindley, Seán, Kelly, Henry A, Lowdon, Andrew W, McDonald, Edward, Mitchell, William L, Pegg, Neil A, Procopiou, Pan A, Ramsden, Nigel G, Thomas, Rhian, Walker, Dawn A, Watson, Nigel S, Jhoti, Harren, Mooney, Christopher J, Tang, Chi-Man, Thomas, Pamela J, Parry, Simon, and Patel, Champa

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results